Home » K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED

K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED

June 16, 2006

Analysts at Deutsche Bank Securities maintain their "hold" rating on K-V Pharmaceutical. The target price has been reduced from $26 to $20.
Newratings

KEYWORDS Daily International Pharma Alert

Upcoming Events

17Mar
FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers
19Mar
SOPs and Policies for the 21st Century: Why Less is More
20Apr
17th Annual Medical Device Quality Congress

New!

17th Medical Device Quality Congress

Learn More Here

K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED

Upcoming Events

FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

SOPs and Policies for the 21st Century: Why Less is More

17th Annual Medical Device Quality Congress

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

CDER Launches Program to Tackle Controlled Substance Abuse

Dexcom’s Continuous Glucose Monitoring System Grabs CE Mark

Janssen to Work with HHS on Coronavirus Vaccine, Vows to Manufacture It

Canon Receives 510(k) Clearance for AI-Assisted CT System

New!

17th Medical Device Quality Congress